Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on February 16, 2023. The filing reports on corporate governance actions taken by the Compensation Committee of the Board of Directors regarding equity compensation grants.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of stock option grants rather than financial performance metrics.
Material Changes and Equity Grants
On February 16, 2023, the Company approved the following stock option grants under its 2021 Stock Incentive Plan (and prior plans for one director), with an exercise price of $9.74 per share:
- Non-Employee Directors: Each director received an option to purchase 35,000 shares, except for Marcia Allen, who received a total of 35,000 options split across the 2021 (19,024), 2019 (7,313), and 2017 (8,663) plans.
- Executive Officers: Ramond J. Tesi (CEO) and David Moss (CFO) each received an option to purchase 160,000 shares.
Vesting Schedule: For all grants, one-third (1/3) vests on the one-year anniversary of the grant date. The remaining options vest monthly (1/24th per month) thereafter, reaching 100% vesting on the three-year anniversary.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on business strategy, or specific risk factors. The document serves solely to disclose the execution of stock option agreements.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2021, 2019, and 2017 Stock Incentive Plans to assess remaining availability.
- Confirm the fair value of the granted options and the resulting stock-based compensation expense impact on future earnings.
- Review the specific terms of the option agreements filed as Exhibits 10.1 and 10.2 for any performance conditions or acceleration clauses not detailed in the summary.
- Check the Company's most recent 10-K or 10-Q for the latest financial position, as this 8-K contains no financial statements.